Drug Profile
Research programme: Del-1 therapeutics - Urigen Pharmaceuticals
Alternative Names: Del-1 antibody - Urigen; Del-1 protein - UrigenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Vanderbilt University
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inducing agents; Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemia; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemia in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 30 Jul 2007 Valentis is now called Urigen Pharmaceuticals